Targeted therapies accounted for about 90% of new active substance approvals in oncology between 2011 and 2018. By March 2021 there were 27 targeted therapies approved for breast cancer.
Value of Life Sciences Innovation
Other featured articles
Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19
This Schaeffer Center white paper highlights the importance of investing in minimally invasive technologies that will allow hospitals to prepare for future surges.
Create a U.S. Institute of Health Technology Assessment to Preserve Innovation and Control Costs
Americans need affordable, accessible and innovative health care. An important first step that can be taken without risking heavy-handed intervention is for Congress to establish an independent Institute of Health Technology Assessment.
Health Technology Assessment in the U.S. – A Vision for the Future
Health technology assessment (HTA) can help achieve the dual health policy goals of ensuring affordability and encouraging innovation.